中文摘要：

目的探讨多种肿瘤标志联合检测在肺癌诊断中的临床价值。方法回顾性分析2010年6月～2010年11月在郑州大学第五附属医院呼吸内科住院治疗的30例肺癌患者和30例良性肺疾病患者血清中糖类抗原19-9（CA19-9）、癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）及糖类抗原125（CA125）4项肿瘤标志的水平及临床资料。结果两组血清CEA含量比较差异无统计学意义（P〉0.05）,其余3种肿瘤标志肺癌组均高于肺良性疾病组,差异均有统计学意义（P〈0.05）;联合检测血清CA19-9,CEA,NSE及CA125,对肺癌诊断的敏感性为50%,特异度为93.33%,准确度为73.33%。结论 4项肿瘤标志联合检测可显著提高肺癌诊断的临床价值,优于单项检测,为肺癌辅助诊断及鉴别诊断提供了有力的依据。

英文摘要：

Objective To study the clinical value of the combined detection of tumor markers in the diagnosis of lung cancer. Methods The clinical data and serum levels of CA19-9,CEA,NSE and CA125 of 30 patients with lung cancer and 30 patients with benign lung disease were retrospectively reviewed from June,2010 to Nov.2010. Results The levels of serum CA19-9,NSE and CA125 in lung cancer group were significantly different from benign lung diseases group（P0.05）.The sensitivity,specificity and accuracy of four tumor markers were 70%,93.33% and 81.67%,respectively. Conclusion The combined detections of CA19-9,CEA,NSE and CA125 are very useful for the diagnostic value of lung cancer patients which will provide a scientific and reliable evidence for differentiating lung cancer from benign lung disease.